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METHODS: Using Surveillance, Epidemiology, and End Results (SEER) cancer regis-
try data linked to Medicare claims, we identified 1,117 FL patients diagnosed be-
tween 01/99 and 12/05. Patients were included if chemotherapy began within 90
days of cancer diagnosis and consisted of CHOP (cyclophosphamide [C], doxorubi-
cin, vincristine [V], and prednisone [P]) or CVP rituximab. Monthly Medicare paid
amounts were calculated for each of 48 monthly partitions following chemother-
apy initiation. To account for censoring we conducted 48 inverse probability-
weighted (IPW) least-squares regression analyses to examine patient factors asso-
ciated with cumulative costs after each partition. Total costs were divided into
chemotherapy and non-chemotherapy. Overall survival was estimated using Ka-
plan-Meier analysis. RESULTS: The median age was 73 years, 56% were diagnosed
with stage III-IV disease, 67% received rituximab, and, among these, the average
cost of rituximabwas $17,958 during the first 12months of frontline therapy. In IPW
regression, the incremental cumulative total cost associated with rituximab was
$20,622 (95% Confidence Interval [CI] $16,999-$24,092) at month 6, $19,606 (95% CI
$14,996-$23,914) at month 12, and $18,122 (95% CI $8,110-$27,533) at month 48.
Other factors associated with higher costs were later cancer stage and higher co-
morbidity index. The cumulative chemotherapy cost associated with rituximab
was $18,109 (95%CI $16,081-$20,365) atmonth 6, $16,249 (95%CI $13,820-$19,023) at
month 12, and $16,130 (95% CI $11,320-$21,015) at month 48. There were no differ-
ences in cumulative non-chemotherapy costs associated with rituximab at any
time. Kaplan-Meier 48-month survival was 74.4% for rituximab and 62.6% for non-
rituximabpatients.CONCLUSIONS:Thenet cost of rituximab is consistentwith the
cost of rituximab treatment, suggesting that over 48 months additional costs from
improved survival were balanced by the reduced need for medical services.
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OBJECTIVES: To compare erythropoiesis-stimulating agent (ESA) dosing patterns
and costs in inpatients with chronic kidney disease (CKD) not on dialysis or with
chemotherapy-induced anemia (CIA).METHODS: Electronic records from the Pre-
mier Perspective Comparative Hospital Database (2006Q1-2009Q4) were analyzed
to identify inpatients 18 years old treated with epoetin alfa (EPO) or darbepoetin
alfa (DARB). Patients receiving renal dialysis or treated with both ESAs were ex-
cluded. CKDpatients had1 claim for CKD, no claim for cancer, and did not receive
chemotherapy. CIA patients had1 claim for cancer, received chemotherapy, and
had no claim for CKD. The mean cumulative ESA dose was used to calculate costs,
based on April 2010 wholesale acquisition costs (EPO: $15.15/1,000 Units, DARB:
$4.96/mcg). RESULTS: A total of 148,746 CKD (EPO: 116,017; DARB: 32,729) and
13,832 CIA (EPO: 10,454; DARB: 3,378) patients were identified. EPO patients were
slightly younger than DARB patients in the CKD group (years: 71.0 vs. 71.2; P.0199)
and slightly older in the CIA group (years: 60.7 vs. 59.2; P.0001). The proportion of
females was higher in CKD (EPO 52.3% vs. DARB 51.3%; P.0018) and similar in CIA
(EPO 52.9% vs. DARB 53.8%; P .3722). The mean length of stay (LOS) was slightly
longer for EPO patients (days: CKD: 9.9 vs. 9.7, P.0006; CIA: 13.4 vs. 12.6; P.0028).
The mean cumulative dose was EPO 37,333 Units and DARB 149 mcg for CKD pa-
tients, and EPO 62,605Units andDARB 272mcg for CIA patients, yielding dose ratios
of 251:1 and 230:1 (Units EPO:mcg DARB), respectively. Corresponding ESA costs
were higher for DARB than for EPO in both populations (CKD: $739 vs. $566; CIA:
$1,349 vs. $948). CONCLUSIONS: This analysis reported dose ratios of 251:1 and
230:1 and a cost premium associated with DARB of 31% and 42% for CKD and CIA
inpatients, respectively, despite longer LOS for EPO patients.
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OBJECTIVES: The novel chemotherapy agent pemetrexed combined with cisplatin
and the vascular endothelial growth factor (VEGF)-targeted agent bevacizumab
combined with cisplatin and gemcitabine are approved as first-line treatments for
patients with non-squamous non-small cell lung cancer (NSCLC). Recent studies
have claimed that bevacizumab has equivalent safety and is cost-saving when
comparedwith pemetrexed in this population. This study analyzed the health care
costs in Russia based on the indirect analysis and local treatment practice. Safety
and efficacy were also compared.METHODS: As no direct head-to-head trials have
been undertaken comparing the two regimens, an indirect treatment comparison
approach was used. Data from 2 separate studies, that had a common comparator
(cisplatin/gemcitabine), were analyzed. Only the 7.5 mg bevacizumab arm was
included. The cost analysis comprised chemotherapy and adverse event treatment
costs. Chemotherapy costs were based on the average number of cycles in the
trials. Safety and efficacy endpoints were matched from the available data. Previ-
ous studies had assumed equivalent safety and used median number of cycles for
the calculation of drug costs when the cycles of bevacizumab are not normally
distributed. RESULTS: The overall proportion of patients suffering a severe adverse
event was significantly lower with pemetrexed (10.50; 95%CI 18.4, 2.71). No
significant differences were found in overall survival (HR 0.90; 95%CI 0.72, 1.13),
although in the individual trials only pemetrexed demonstrated significant sur-
vival advantage (HR 0.84; 95%CI 0.74, 0.96) while 7.5 mg bevacizumab showed no
survival advantage (HR 0.93; 95%CI 0.78, 1.11). When costs were based on the aver-
age number of cycles used on a per-patient basis (4.3 vs. 7.2), pemetrexed was
cost-saving (saving R337,600 or $US11,100) with most savings from chemotherapy
costs to pharmacy (R334,100 or $US10,900). CONCLUSIONS: Pemetrexed is cost-
saving and less toxic compared to bevacizumab in this patient population, and
produces at least equal survival outcomes.
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OBJECTIVES: Coloretal cancer (CRC) is one of the most common and costly cancer
in the United States. 70% of the patients are diagnosed post 65 years old. This study
used a large cohort of patients from 2005-2008 100% Medicare Institutional Inpa-
tient and Outpatient data to estimate the cost of different treatments and under-
stand the chemotherapy use for CRC patients. METHODS: 203,532 (50.8% Female)
CRC patients that were age 65 or older with a mean Charlson Comorbidity Index
(CCI) of 2.30 ( 3.26) were identified by ICD-9 code 153.x and/or 154.x. The overall
cost for patient groups with different characteristics was compared by using stan-
dard t-test,Wilcoxon test or ANOVA. The costwas furthermodeled in a generalized
linear model (GLM) with a log-link and gamma distributed variance functions.
RESULTS: 38% of CRC patients had surgery, 6.0% conducted radiotherapy and 5.7%
received chemotherapy. Patients on chemotherapy were incurred with the highest
cost ($41,867), followed by radiotherapy ($13,812) and surgery ($4,964). Patients on
5-FU, Leucovorin, Oxaliplatin and Bevacizumab (5-L-O-B) had the highest esti-
mated cost ($52,158), as its patient populationwas themost severe (Mean CCI7.6),
followed by 5-FU, Leucovorin and Oxaliplatin (5-L-O) ($39,435, Mean CCI4.6). The
average cost for other chemotherapies was $30,838. Most colon cancer patients
(2,761 patients) used the drug combination of 5-L-O and 5-L-O-B (1,450 patients).
Oxaliplatin and Bevacizumab were administered at a lower dose when used in
combination with other drugs than used alone. About 60% of the patients received
these combinations as adjuvant therapy after surgery. CONCLUSIONS: This study
provided information on the average annual cost of elderly CRC patients by treat-
ment type and disease comobidity. The analysis illustrated the utilization of che-
motherapy in CRC treatment: the common drug combinations and its costs, dosing
and administration information as well as chemotherapy use after surgery.
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OBJECTIVES: The first year after cancer diagnosis is a period of intensive treatment
and high cost. Our objective is to estimate the first year costs for patients initially
diagnosed with one of the 19 most common cancers in Ontario between 1997 and
2007. METHODS: We selected patients who were diagnosed at 19 years of age or
older, with valid ICD-O and histology codes, who survived more than 30 days after
diagnosis, and had no second cancer within 90 days of the initial cancer from the
Ontario Cancer Registry (N 412,787). We linked these patients to health care ad-
ministrative databases, and radiation therapy data from Cancer Care Ontario. We
defined the health care resources to be costed and developed suitable costing
methodologies. We examined health care resource use and calculated mean costs
for each type of cancer in the first year after diagnosis. RESULTS: Patients with
myeloma and brain cancer incurred the highest mean first-year costs ($71,892
and $65,629, respectively); patients with melanoma, uterine and prostate can-
cers had the lowest mean costs ($21,050, $29,115 and $29,309 respectively). The
most costly resources for all cancer types were hospitalizations (38% of total
costs) and physician services (28% of total costs). Surprisingly, chemotherapy
and radiation therapy contributed very little to the total (4% and 1%, respec-
tively). Previous research on first-year costs for patients aged 65 in the US also
found that brain and other nervous system cancers had the highest cost of care
while melanoma of the skin had the lowest cost; hospitalization was also the
costliest resource. CONCLUSIONS: The first-year costs of cancer care in Ontario
are substantial and vary by tumour site. Hospitalizations and physician services
comprise a large portion of the costs for all cancer types. These estimates will
improve the quality of future cancer-related economic evaluations and are of value
to researchers and policy makers.
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OBJECTIVES: Recent research describes decreasing quality of life for patients with
CRPC at the end of life, but less is known about accompanying changes in health
care costs. This study aimed to examine costs at the end of life for patients with
CRPC who died compared to patients alive at the end of the study period.
METHODS: A retrospective study design used medical and pharmacy claims and
lab results (2001-2007) to identify patients with CRPC from a large U.S. managed
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care health plan; patientswere followed until death, disenrollment from the health
plan, or 12/31/2008. Health care costs in the 24 months prior to death/end of fol-
low-up were calculated, divided into 4-month periods to assess trends over time.
Chi-square statistics were used to compare patients who died vs. those alive at the
end of the study on health care costs, comorbidity, clinical, and demographic
characteristics. RESULTS: 260 CRPC patients died, with 2304 patients alive at the
end of the study (mean age 73.99 vs. 72.63 years, p0.035). 2 years prior to death/
end of follow-up, comorbidity scores were similar and mean total costs per
4-month period were not significantly different for patients who died vs. those
alive ($8,292 vs. $6,809, p0.060). Health care costs increased prior to death, with
the sharpest increase in the last 4-months of life with mean costs roughly tripling
(from $15,185 to $44,203). For patients who did not die, mean total costs increased
by one-third in each 4-month period, from$6,809 to $13,170 at the end of follow-up.
CONCLUSIONS: Although costs were initially similar for CRPC patients who died
compared to patients alive at study end, patients who died had significantly larger
increases in costs over the 2-year period, with the sharpest increase in the last year
prior to death.
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OBJECTIVES: 7,538 new cases of SCCHN were diagnosed in 2006 and 2,594 deaths
reported in 2007 in the UK. For patients with resectable SCCHN surgical resection
followed by postoperative radiation therapy remains a common treatment ap-
proach. For locoregional disease control chemotherapy is also an important treat-
ment component. METHODS: This retrospective analysis was based on inpatient
and outpatient records extracted from Hospital Episode Statistic database. SCCHN
patients with resection of oral cavity, pharynx or larynx between 2003-07-01 and
2008-03-31 were followed for at least one year (max. of 5 years) from the surgery
date. RESULTS: There were 38,460 patients diagnosed with SCCHN in the dataset.
11,403 patients met the inclusion criteria for the study. Mean age was 63.2 years
and 69.8% were male. Mean length of follow-up was 31.0 months. In the first year,
mean length of hospitalizationwas 21.6 days andmeannumber of outpatient visits
was 4.2. Mean number of reconstructive and secondary surgeries per patient was
0.32 and 0.14, respectively in the first year. Mean number of radiotherapy and
chemotherapy sessions per patient was both 0.45 in the first year. Total costs of
post-operative healthcare utilization in the patient cohort was £249.4 million over
5 years with 90% (£225.5 million) occurring within the first year. Mean cost was
£19,778 for the first year and £1477, £847, £653 and £455 for years 2-5. Inpatient care
costs accounted for 96% of total costs with hospitalization contributing to 85% of
these costs.CONCLUSIONS:Given limited outpatient data in theHES, radiotherapy
and chemotherapy utilization and costs in the outpatient setting are likely to be
underestimated. However, results still indicate that treatment of resected SCCHN
in the UK is associated with significant healthcare utilization and costs. This sug-
gests the need for new therapies that could improve outcomes and reduce the
economic burden.
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OBJECTIVES: Out-of-pocket (OOP) medical expenditures of families may pose a
financial burden, particularly to the seriously ill. The objective of this study was to
analyze financial burden among patients with three common cancers: breast can-
cer (BC), colorectal cancer (CRC), and lung cancer (LC). METHODS: This study in-
cluded respondents in the US Medical Expenditure Panel Survey who had 1 BC
(ICD-9-CM 174.xx), CRC (ICD-9-CM 153.xx, 154.xx), or LC (ICD-9-CM 162.xx) diagno-
sis between 1996 and 2007. Matched comparison cohorts (without cancer) were
constructed for each cancer type, based on age, payor, sex, race and region. All
years of datawere pooled andweighted to create nationally representative average
annual estimates reported in 2009 USD. OOP family medical expenditures (not
including premiums), and family income were analyzed. Families were defined as
having a highOOP burden if their OOP expenditures exceeded 10% of annual family
income (5% if low income). RESULTS: 1,849 patients with cancer were identified
(1,083 BC, 467 CRC, 299 LC). Total OOP expenditures averaged $3,400 - $4,400 for
cancer patients versus $2,100 - $2,700 for controls. Overall, 31-37% of cancer pa-
tients had high OOP burden (31% BC, 37% CRC, 35% LC), compared to about a
quarter of matched comparison patients. Among those under age 65, 16-30% of
privately insured hadhigh burden. Among those 65,moreMedicare-only patients
had high burden (48-53%) compared to those with Medicare plus other insurance
(29-36%). CONCLUSIONS: Over a third of cancer patients have OOP expenditures
greater than 5-10% of their household income. Privately insured patients appear
least likely to have high burden while publicly insured appear most likely. To
ensure that cancer patients can adequately access needed medical care, explora-
tion of how US health reform or other policy options could reduce this financial
burden is warranted.
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OBJECTIVES:Monoclonal antibodies improve treatment outcomes in patients with
metastatic colorectal cancer (mCRC); they have distinct and known safety profiles
that may be associated with toxicities requiring hospitalization, which likely fur-
ther impact cost of patient care. The objective of this study was to determine
hospital costs of these events.METHODS: From the PHARMO Record Linkage Sys-
tem, including drug dispensing and hospitalization records of approximately 3.2
million residents in The Netherlands, all patients with a primary or secondary
hospital discharge code for CRC and distant metastasis between 2000 and 2008
were defined as patients with mCRC. The first discharge diagnosis defining metas-
tases served as the index date. Patients were followed from index date until end of
data collection, death, or end of study period, whichever occurred first. Main out-
comes for each identified event were length of stay (days) and costs per hospital
admission (€). All results are presented descriptively. RESULTS: Among 2,964 pa-
tients with mCRC identified, 271 hospital events occurred during a median fol-
low-up of 24 months. The longest mean ( SD) lengths of stay per hospital admis-
sion were for stroke (16 ( 33) days) and arterial thromboembolism (ATE) (14 ( 21)
days), followed by wound healing complications (WHC), acute myocardial infarc-
tion (AMI), congestive heart failure (CHF), and neutropenia (all 9 days with SD 5 to
15). Highest mean ( SD) costs per admission were observed for stroke (€13,500 (
€28,800)), ATE (€13,300 ( €18,800)), andWHC (€10,800 ( €20,500)), followed by AMI
((€9,000 ( €7,300)), neutropenia (€7,900 ( €4,400)), and CHF (€7,700 ( €6,300)).
Lowest mean ( SD) costs were for dermatological toxicity (€5,400 ( €5,200)) and
hypertension (€4,100 ( €2,800)). CONCLUSIONS: Inpatient costs for events in pa-
tients with mCRC are considerable and vary greatly. Such data are valuable to the
pharmacoeconomic evaluations of newer treatments in patients with mCRC.
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OBJECTIVES:To study themedical expenditure of insured patientswith cancer and
its influence factors, to analyze the utilization of pharmaceuticals, treatment-seek-
ing behavior and the relationship between the medical expenditure and payment
patterns ofmedical insurance.METHODS:This study involved 5351 cancer cases in
3 municipalities (Beijing, Shanghai, Chongqing) and 5 province-capital cities (She-
nyang, Fuzhou, Jinan,Zhengzhou, Xining).The actual claim data of their medical
expenditure and medical care utilization in 2008 were collected. Descriptive anal-
ysis and multivariate linear regression analysis were applied. RESULTS: 1) Outpa-
tient’s annual medical expenditure per head was US$802 and inpatient’s annual
medical expenditure per head was US$6200. Although the basic medical insurance
(BMI) fund covered about 70% of the expenditure, the patients’ economic burden is
still heavy. 2) Western medicine cost accounted for 44% to 60% of the inpatients’
medical expenditure in various cities. Cytotoxic drug usage accounted for over 80%
of the anti-tumor drugs. 3) The proportion of the patients who sought outpatient
and inpatient treatment in the third level hospitals was 81% and 74%, respectively.
4) Multivariate linear regression analysis showed that themain influence factors of
inpatients’ medical expenditure include medical insurance payment pattern, hos-
pital level, category of cancer, gender, length of stay in hospital, and medical in-
surance type. When all factors other than payment pattern were set to be control
parameters, inpatient’s annual medical expenditure per head under flat rate pay-
ment was US$348 lower than that under fee-for service. CONCLUSIONS: Medical
expenditure causes heavy burden for cancer patients and the BMI fund. Flat rate
payment has proved to be more effective in expenditure control compared with
fee-for service. To keep the fund safe and running effectively, it is necessary to
adjust present payment patterns and set rational payment standard to encourage
medical care providers to control the expenditure actively.
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HEALTH CARE EXPENDITURES, DISABILITY DAYS, AND RESOURCE
UTILIZATION ASSOCIATED WITH CANCER IN EMPLOYER SETTINGS IN THE
UNITED STATES
Tang D1, Alberts DS1, Nevins R2, Sullivan S2, Skrepnek GH1
1The University of Arizona, Tucson, AZ, USA, 2Institute for Health and Productivity
Management, Scottsdale, AZ, USA
OBJECTIVES: To assess healthcare expenditures, disability days, and resource uti-
lization in persons with cancer that were employed within large and small organi-
zations in the United States. METHODS: This retrospective database analysis uti-
lized 2007 Agency for Healthcare Research and Quality (AHRQ) Medical
Expenditure Panel Survey (MEPS) public-use data. Inclusion criteria included age
18 years, any diagnosis of malignant neoplasms (including both new cases and
those continuing treatment), and employment within either large or small organi-
zations (500 or 500 employees, respectively). Regression analyses were per-
formed via gamma or negative binomial generalized linearmodels for outcomes of
total direct healthcare expenditures, number of disability days, and summed re-
source utilization (outpatient visits, emergency department visits, hospitaliza-
tions) after controlling for predominant cancer types and other factors including
demographics (age, sex, race, education, region, income, residence), insurance cov-
erage, employer size, perceived health status, secondary malignancies, and the
D’Hoore-Charlson Comorbidity Index. To provide national estimates, all results
were weighted and used standard errors (SE) calculated via Taylor-series
approaches. RESULTS: Overall, 3.86 million employed adults in the US had new or
continued cases of cancer in 2007, averaging 54.0 (SE0.9) years of age, 9.3 (SE1.8)
disability days, and $15,365 (SE2921) in expenditures. Mostwere employedwithin
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